abstract |
The present invention relates generally to methods for the treatment and diagnosis of conditions mediated by IL-5 and excessive production of eosinophils, and more specifically with mAbs, Fabs, chimeric and humanized antibodies; more particularly, the present invention generally relates to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or a fragment thereof. |